Close
Nordic 9Nordic 9

Roche Venture Fund (investor - Corporate Investor)

Switzerland roche.com
See something wrong or missing? Let us know
Offices:Basel, San Francisco

Roche Venture Fund is a Swiss, CHF 500M ($520M) corporate venture fund of Roche, a global leader in bringing medicines and in vitro diagnostics to the benefit of patients. The company invests in life science companies in both pharmaceuticals and diagnostics.

Average round investment:54.08M USD
Average number per year:1.7
Distribution: 2025 (3)2024 (1)2023 (3)2022 (1)2021 (2) See the entire list
Portfolio companies: United Kingdom Mission TherapeuticsSpain Splice BioSwitzerland GlycoEra See the entire list
Mostly invests in: United Kingdom United Kingdom (4) Health services (11)
See the entire list

Showing 3 of 12 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Roche Venture Fund mostly invests with:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Roche Venture Fund

Name Criteria
Germany Evonik Venture Capital GmbH
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Denmark, France
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
Spain Aliath Bioventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Spain
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
Belgium VIB
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Denmark
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
United States Surveyor Capital
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Denmark, Switzerland
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
United States Bristol-Myers Squibb
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Denmark, France
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
United Kingdom Isomer Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.6
  • Active last 12 months: Yes
United States +ND Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Denmark, Switzerland
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
United States Versant Ventures
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Denmark, Switzerland
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
United States Lightstone Ventures
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.6
  • Active last 12 months: Yes
Belgium European Investment Fund
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: France, Italy
  • Average number of deals per year: 1.9
  • Active last 12 months: Yes
Top